Table 3.
Tolerability and Efficacy of Intraperitoneal Treatment with Oxaliplatin Derivatives Compared to Oxaliplatin in L1210 Leukemia-Bearing Mice (Therapeutic Effects at the Respective Optimum Dose Are Marked in Bold Type)
| compd | dose (mg/kg/day) | min body weight (%) | toxic deaths | ILS (%)a | long-term survivorsb |
|---|---|---|---|---|---|
| oxaliplatin | 9 | 6/6 | 0/6 | ||
| 6 (MTD)c | 93.2 | 0/6 | 152 | 2/6 | |
| 4.5 | 91.3 | 0/6 | 89 | 1/6 | |
| 3 | 94.1 | 0/6 | 94 | 1/6 | |
| d-OHP | 12 | 1/6 | 0/6 | ||
| 9 (MTD)c | 85.9 | 0/6 | 63 | 0/6 | |
| 6 | 93.1 | 0/6 | 73 | 1/6 | |
| 4.5 | 93.6 | 0/6 | 26 | 0/6 | |
| 3a | 12 | 2/6 | 4/6 | ||
| 9 (MTD)c | 88.6 | 0/6 | > 200 | 5/6 | |
| 6 | 97.5 | 0/6 | 119 | 0/6 | |
| 4.5 | 94.6 | 0/6 | 84 | 1/6 | |
| 3 | 97.3 | 0/6 | 90 | 0/6 | |
| 3b | 9 | 1/6 | 0/6 | ||
| 6 (MTD)c | 92.0 | 0/6 | 103 | 1/6 | |
| 4.5 | 93.4 | 0/6 | 68 | 2/6 | |
| 3 | 97.9 | 0/6 | 68 | 1/6 | |
| 3c | 12 | 2/6 | 1/6 | ||
| 9 (MTD)c | 86.4 | 0/6 | 122 | 2/6 | |
| 6 | 87.3 | 0/6 | 78 | 1/6 | |
| 4.5 | 87.9 | 0/6 | 111 | 2/6 | |
| 4 | 12 | 83.2 | 0/6 | 144 | 2/6 |
| 9 (MTD)c | 89.9 | 0/6 | 129 | 1/6 | |
| 6 | 93.6 | 0/6 | 89 | 0/6 | |
| 3 | 98.4 | 0/6 | 61 | 0/6 | |
| 5 | 12 | 100.0 | 0/6 | 33 | 0/6 |
| 6 | 100.0 | 0/6 | 25 | 0/6 | |
| 3 | 98.5 | 0/6 | 17 | 0/6 |
a
Increase in life span compared to untreated controls, based on median survival; all values indicate life prolongation with high statistical significance (p < 0.001).
b
Animals with ILS > 200% without any signs of leukemia.
c
Maximum tolerated dose.